Literature DB >> 25646269

Spectrum of disease outcomes in mice infected with YFV-17D.

Andrea K Erickson1, Julie K Pfeiffer1.   

Abstract

The host and viral factors that influence disease outcome during flavivirus infections are not fully understood. Using the live attenuated yellow fever virus (YFV) vaccine strain 17D as a model system we evaluated how viral dose, inoculation route and immunopathogenesis contributed to disease outcome in mice deficient in the type I IFN response. We found that YFV-17D infection of IFN-α/β receptor knockout mice resulted in three distinct disease outcomes: no clinical signs of disease, fatal viscerotropic disease or fatal neurotropic disease. Interestingly, viral load at disease onset did not correlate with disease outcome. However, we found increased immune infiltrates in the brain tissues of mice that developed neurotropic disease. Additionally, mice that developed viscerotropic disease, as characterized by liver and spleen pathology and/or intestinal haemorrhage, had significantly elevated levels of alanine aminotransferase, monocyte chemotactic protein and IFN-inducible protein (IP)-10 as compared with mice with no clinical signs of disease or neurotropic disease. Furthermore, mice treated with recombinant IP-10 throughout YFV-17D infection showed increased mortality and an increased percentage of mice with viscerotropic disease. Our results demonstrated that viral load did not correlate with pathogenesis, and the host immune response played a pivotal role in disease outcome and contributed to YFV-17D pathogenesis in mice.
© 2015 The Authors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25646269      PMCID: PMC4635484          DOI: 10.1099/vir.0.000075

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  14 in total

Review 1.  Host genetic control of mosquito-borne Flavivirus infections.

Authors:  Caroline Manet; Claude Roth; Ahmed Tawfik; Tineke Cantaert; Anavaj Sakuntabhai; Xavier Montagutelli
Journal:  Mamm Genome       Date:  2018-08-25       Impact factor: 2.957

2.  Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection In Vivo.

Authors:  Florian Douam; Yentli E Soto Albrecht; Gabriela Hrebikova; Evita Sadimin; Christian Davidson; Sergei V Kotenko; Alexander Ploss
Journal:  mBio       Date:  2017-08-15       Impact factor: 7.867

3.  Human immune cell engraftment does not alter development of severe acute Rift Valley fever in mice.

Authors:  Jessica R Spengler; Anita K McElroy; Jessica R Harmon; JoAnn D Coleman-McCray; Stephen R Welch; James G Keck; Stuart T Nichol; Christina F Spiropoulou
Journal:  PLoS One       Date:  2018-07-20       Impact factor: 3.240

4.  Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models.

Authors:  Fabienne Piras-Douce; Franck Raynal; Alix Raquin; Yves Girerd-Chambaz; Sylviane Gautheron; Martha Erika Navarro Sanchez; Manuel Vangelisti; Nathalie Mantel
Journal:  Vaccine       Date:  2021-03-06       Impact factor: 3.641

Review 5.  Viral infections in humans and mice with genetic deficiencies of the type I IFN response pathway.

Authors:  Isabelle Meyts; Jean-Laurent Casanova
Journal:  Eur J Immunol       Date:  2021-04-04       Impact factor: 5.532

6.  Selective expansion of myeloid and NK cells in humanized mice yields human-like vaccine responses.

Authors:  Florian Douam; Carly G K Ziegler; Gabriela Hrebikova; Bruno Fant; Robert Leach; Lance Parsons; Wei Wang; Jenna M Gaska; Benjamin Y Winer; Brigitte Heller; Alex K Shalek; Alexander Ploss
Journal:  Nat Commun       Date:  2018-11-28       Impact factor: 14.919

7.  Multimodal assessments of Zika virus immune pathophysiological responses in marmosets.

Authors:  Fok-Moon Lum; Wei Zhang; Kheng-Choon Lim; Benoit Malleret; Teck-Hui Teo; Jun-Jia Koh; Kuan J Lee; Tze-Kwang Chua; Yiu-Wing Kam; Wearn-Xin Yee; Isaac Huen; Jeslin J L Tan; Siti Naqiah Amrun; Bhanu Prakash Kn; Patrick J Cozzone; Laurent Renia; Philip T H Lee; Lisa F P Ng
Journal:  Sci Rep       Date:  2018-11-20       Impact factor: 4.379

8.  A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies.

Authors:  Niraj Mishra; Robbert Boudewijns; Michael Alexander Schmid; Rafael Elias Marques; Sapna Sharma; Johan Neyts; Kai Dallmeier
Journal:  mBio       Date:  2020-04-07       Impact factor: 7.867

Review 9.  Genetic Lesions of Type I Interferon Signalling in Human Antiviral Immunity.

Authors:  Christopher J A Duncan; Richard E Randall; Sophie Hambleton
Journal:  Trends Genet       Date:  2020-09-22       Impact factor: 11.639

10.  Consumptive coagulopathy of severe yellow fever occurs independently of hepatocellular tropism and massive hepatic injury.

Authors:  Adam L Bailey; Liang-I Kang; Luiz Gonzaga Francisco de Assis Barros D'Elia Zanella; Cássia G T Silveira; Yeh-Li Ho; Lander Foquet; Greg Bial; Broc T McCune; Amaro Nunes Duarte-Neto; Archana Thomas; Hans-Peter Raué; Kathleen Byrnes; Esper G Kallas; Mark K Slifka; Michael S Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-02       Impact factor: 12.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.